Skip to main content
. Author manuscript; available in PMC: 2014 Mar 15.
Published in final edited form as: ACS Chem Biol. 2012 Dec 11;8(3):578–587. doi: 10.1021/cb300568r

Figure 5.

Figure 5

TCH-013 delays tumor growth in an RPMI-8226 xenograft mouse model. The anti-tumor activity of TCH-013 against established RPMI-8226 human MM in female NIH-III mice was evaluated as described in materials and methods. TCH-013 was administered IP at 150 mg/kg twice daily. Bortezomib was administered intravenously twice weekly at the maximum tolerated dose. Tumor burden (mg) = (L X W2)/2, where L and W are the respective orthogonal tumor length and width measurements (mm). Shaded area included treatment days.